TABLE 4.
Yearly susceptibility rates for P. aeruginosa isolates from U.S. medical centers (2012 to 2015)
| Antimicrobial agent or phenotype | % susceptiblea/frequency by yr (no. of isolates) |
|||
|---|---|---|---|---|
| 2012 (1,966) | 2013 (1,935) | 2014 (1,742) | 2015 (1,809) | |
| Ceftazidime-avibactam | 96.9 | 96.8 | 96.3 | 98.0 |
| Ceftazidime | 83.2 | 84.3 | 84.0 | 85.8 |
| Cefepime | 83.8 | 83.5 | 86.6 | 87.9 |
| Piperacillin-tazobactam | 78.3 | 78.7 | 83.0 | 82.5 |
| Meropenem | 82.0 | 81.9 | 83.1 | 80.9 |
| Ciprofloxacin | 77.5 | 76.6 | 77.8 | 78.1 |
| Levofloxacin | 75.3 | 74.5 | 75.1 | 74.7 |
| Gentamicin | 88.8 | 89.0 | 88.0 | 87.2 |
| Amikacin | 97.5 | 97.3 | 96.8 | 96.4 |
| Colistin | 98.7 | 99.9 | 99.1 | 99.9 |
| MDR phenotype | 15.7 | 16.1 | 15.9 | 14.4 |
| XDR phenotype | 10.1 | 9.1 | 9.8 | 8.4 |